CEPI
New vaccines for a safer world

John-Arne Røttingen, CEO
September 29, 2016
The challenge of epidemics
Calls for global action

Outcome document
Financing of R&D Preparedness and Response to Epidemic Emergencies
October 29-30, 2015
Oslo, Norway

Background
This Outcome document summarizes discussions that took place during the Oslo consultation on Financing of R&D Preparedness and Response to Epidemic Emergencies (October 29-30, 2015). It reflects views expressed and the discussion that took place, but does not necessarily reflect all interventions. Names of representatives of countries and organizations participating in the Oslo consultation on Financing can be found on the webpage of the Norwegian Institute of Public Health. Stakeholders represented included government, industry, NGOs and academia as well as charitable foundations and other relevant actors. The consultation was jointly organized by WHO and the Norwegian Institute of Public Health and hosted by the Norwegian Institute of Public Health.
High Level Meeting Davos 21 January

Task Team Meeting Meeting, Oslo 6-7 April

Task Team Tele-conferences

Leadership Group Meeting Washington DC 17 May

Interim CEO appointed Interim board constituted Business Plan presented to stakeholders
CEPI-actions July - September

Core Group and Leadership Group Teleconferences

First CEPI interim board meeting London, 31 August

CEPI soft launch Media coverage

G7 Health ministers’ side event, Kobe, 10 September

UNGA side event on health emergencies, NY, 19 September
Challenges

1. The pipeline is weak for most emerging infectious diseases characterized by lack of market incentives.

2. Unilateral, uncoordinated government efforts to fund R&D preparedness are inefficient and unsustainable in addressing global epidemic risks.

3. Clinical & regulatory pathways are not easily adaptable to epidemic contexts.

4. Incentives are lacking to motivate greater industry engagement.
Vaccine pipelines

Figure: Vaccine pipelines for priority pathogens included in the WHO R&D Blueprint list as at mid-2016.
Opportunities

1. The Ebola momentum: vaccines are feasible despite a risky development pathway

2. The Ebola momentum: it is possible to advance the clinical development of safe and effective vaccines against EIDs in an emergency

3. R&D actors supporting EID vaccine pipelines: government health research agencies, academic research institutions, biotechs, multinational vaccine manufacturers, and non-profits

4. Manufacturing capability and capacity for vaccines has always been a critical bottle-neck in epidemic events. Major vaccine manufacturers can drive pipelines forward
The CEPI response

Rationalize and accelerate research and development responses to new outbreaks

Coordinate resources of industry, academia, governments, philanthropies, and NGOs

Prioritize platform technology and vaccine targets and facilitate the advanced development of vaccines for emerging infectious diseases
Vaccines contributing to preventing outbreaks from becoming humanitarian crises
Mission

To *stimulate, finance and co-ordinate* vaccine development against emerging infections with epidemic potential, especially in cases where market incentives alone do not achieve this.
Approach

End-to-end approach

1. Move new vaccines through late preclinical studies to proof of concept and safety in humans, and

2. Develop platforms that can be rapidly deployed against known and unknown pathogens.
Strategic objectives

1. Preparedness
2. Response speed
3. Predictability
4. Equity
CEPI fit along the end-to-end spectrum

**CEPI Scope and Fit with other Initiatives**

---

**Significant focus by others**

**Role for CEPI**

**Significant focus by others**

<table>
<thead>
<tr>
<th>Phase</th>
<th>1 Discovery</th>
<th>2 Development/Licensure</th>
<th>3 Manufacturing</th>
<th>4 Delivery/Stockpiling</th>
</tr>
</thead>
</table>
| **Current Stakeholders** | • Academia  
• Governments  
• WT/NIH  
• GLOPID-R  
• Industry  
• Regulators  
• Biotech | • Industry  
• National Governments  
• Regulators  
• Gates  
• BARDA/DTRA etc.  
• WHO  
• Biotech  
• PDPs | • Industry  
• BARDA  
• CMOs  
• Regulators  
• National Governments  
• WHO | • GAVI  
• UNICEF  
• PAHO  
• National Governments  
• WHO  
• Industry  
• Pandemic Emergency Facility (World Bank) |
The CEPI partnership model

CEPI is building capabilities through a mix of partnership models:

1. Advanced Development Partnership (ADP)
2. Targeted investments for filling additional R&D gaps
3. Clinical and regulatory coordination network
4. Complementary coordination initiatives
CEPI’s operating principles

1. Equitable access
2. Cost coverage
3. Shared benefits
Organizational setup: startup phase
CEPI Interim Board

K. Vijay Raghavan, chair
Secretary, Department of Biotechnology
Ministry of Science and Technology, India

Peter Piot, vice chair
Director of the London School of Hygiene and Tropical Medicine

Jane Halton
Permanent Secretary
Department of Finance, Australia

Nicole Lurie
Assistant Secretary,
Department of HHS, US

Tore Godal
Special Adviser on Global Health
Ministry of Foreign Affairs, Norway

Christopher Whitty
Chief Scientific Adviser
Department of Health, UK

Kesetebirhan Admasu
Minister of Health, Ethiopia

Jeremy Farrar
Director, Wellcome Trust

Trevor Mundel
President Global Health Division
The Bill & Melinda Gates Foundation

Adar Poonawalla
CEO and Executive Director
Serum Institute of India

Nima Farzan
President and CEO
PAXVAX INC.

Julie Gerberding
Executive Vice President
Merck

Moncef Slaoui
Chairman of vaccines
GSK

Joanne Liu
International President
Medecins sans Frontieres

Victor Dzau
President of the Institute of Medicine
National Academy of Sciences

Arnaud Bernaert
Head of Global Health and Healthcare Industries
World Economic Forum

Ruxandra Draghia-Akli
Deputy director-general of DG RTD,
European Commission

Yah Zolia
Deputy Minister of Health and Social Welfare
Liberia

Observers
Marie-Paule Kieny
Assistant Director-General
World Health Organization

Mark Feinberg (Chair of SAC)
President & Chief Executive Officer, IAVI

Peggy Hamburg (Chair of JCG)
Foreign Secretary of the Institute of Medicine
National Academy of Sciences

John-Arne Røttingen
Interim CEPI CEO
CEPI interim SAC

Mark Feinberg (Chair)  
International AIDS Vaccine Initiative

Alan D. Barrett  
University of Texas Medical Branch

Amadou Sall  
Institute Pasteur Dakar

Bernard Fanget  
Abivax, Neovacs

Chery Gagandeep Kang  
Christian Medical College Vellore

Connie Schmaljohn  
University of Maryland

Daniel Brasseur  
European Commission

David Kaslow  
PATH/CIVA

David Wood  
World Health Organization

George Fu Gao  
Chinese Center for Disease Control and Prevention

Gunnstein Norheim  
Norwegian Institute of Public Health

Heinrich Feldman  
NIH National Institute of Allergy and Infectious Diseases

Helen Rees  
Wits Reproductive Health and HIV Institute

Jesse Goodman  
Georgetown University

Kathleen Neuzil  
University of Maryland

James Robinson  
James Robinson Biologics Consulting

Maharaj Kishan Bhan  
JIPMER

Peter Smith  
London School of Hygiene and Tropical Medicine

Rick Bright  
Biomedical Advanced Research and Development Authority (BARDA)

Stanley Plotkin  
VaxConsult

Subhash Kapre  
Inventprise
CEPI financing needs

CEPI raising USD 1 billion to support a five year portfolio strategy of two to three prioritized pathogens and two to three phase IIa vaccine candidate targets per prioritized pathogen by the end of this period.

Financing Model
CEPI seeks multi-year donor commitments to satisfy its core financing needs, as well as targets through a multi-source financing model.

Four key financing principles
1. Broad-based financing
2. Long term, predictable financing
3. Complementary and new financing
4. Fit-for purpose financing
Next steps

Start Up Phase

- **Scientific Advisory Committee Meeting, 20 and 21 October**
- **Joint Coordination Group Meeting, 18 November 2016**
- **Secure initial commitments of CEPI participation and contribution**
  - **2nd Interim Board Meeting in India**
  - **16 December 2016**
- **Lead funders to launch CEPI and call for additional participation at the Annual Meeting at Davos, January 2017**

Formalize Commitments

Launch Partnership